Health and Me

Tanya Dutt

RSV Vaccine For Expecting Moms Cuts Risk Of Severe Lung Infections In Infants by 72%; Premature Babies To Be Vaccinated Before Winter

Respiratory syncytial virus, or RSV, is often dismissed as just another cold virus. But in reality, it's the leading cause of hospitalizations for infants under one year of age worldwide. As healthcare systems worldwide wrestle with post-pandemic waves of respiratory illnesses, RSV has emerged as one of the most persistent and potentially dangerous. What’s changing now is how we prevent it—and early data from the United Kingdom shows we might finally be gaining ground.

The latest findings, why RSV matters, and how two vaccines—one for pregnant women and one for premature infants—could turn this virus from a winter threat into a manageable infection.

RSV typically starts with symptoms that resemble a common cold: runny nose, cough, sneezing, fatigue, and sometimes fever. But in infants, especially those born prematurely or with underlying health conditions, it can progress rapidly into bronchiolitis or pneumonia. These conditions can cause breathing distress, feeding difficulties, and—in the worst cases—require intensive care support.

While most full-term babies recover with rest and fluids, around 30,000 children under the age of five are hospitalized every year in the UK due to RSV. Tragically, around 30 of them do not survive. Globally, the burden is even greater, especially in low-resource countries where access to neonatal intensive care is limited.

The UK Health Security Agency’s 2023–2025 report revealed that infectious diseases now account for a fifth of all hospital bed usage, at an annual cost of over $7.7 billion. RSV and flu were major drivers of this surge, particularly during winter.

But amidst the sobering data was a silver lining: a 30% drop in RSV-related hospitalizations among vaccinated seniors aged 75–79. And even more encouraging—when pregnant women were vaccinated against RSV, the risk of their babies being hospitalized with severe infection dropped by a staggering 72%.

This isn’t a small win. It’s a signal that we may finally have tools to lower the burden of RSV across all age groups.

<h2>How Does the Maternal RSV Vaccine Work?</h2>

When a pregnant woman receives the RSV vaccine—currently offered in the UK starting at 28 weeks of pregnancy—her body generates antibodies that are passed to the baby in utero. These antibodies offer a protective buffer against RSV during the first six months of life, when infants are most vulnerable.

Timing matters. The study led by the University of Edinburgh showed the highest level of protection (72%) was seen when the vaccine was given more than two weeks before delivery. Babies whose mothers were vaccinated at any point before birth still had reduced risk, but the impact dropped to 58%.

Despite these results, only about half of pregnant women in England and Scotland are receiving the RSV vaccine. Public health officials are now urging increased uptake to curb RSV admissions this winter.

<h2>What About Premature Babies Who Miss Maternal Immunity?</h2>

Babies born before 32 weeks don’t receive as many antibodies from their mothers, making them extremely vulnerable to RSV. Enter nirsevimab—a monoclonal antibody shot that offers immediate and long-lasting protection, not by training the immune system like a vaccine, but by delivering RSV-blocking antibodies directly.

Starting in September, the NHS will provide nirsevimab to around 9,000 premature babies across the UK. The single injection provides protection for up to six months—precisely the timeframe these infants are at highest risk.

Dr. Claire Fuller, co-national medical director for NHS England, described it as offering “a protective bubble” for at-risk newborns. And early data suggests the drug is more than 80% effective at preventing severe RSV-related illness.

Hospitals aren’t just overwhelmed by RSV because of its severity—it’s the sheer volume of cases. Every winter, thousands of RSV cases flood pediatric wards, straining resources, delaying elective procedures, and stressing staff.

With effective maternal vaccination and early protection for preemies, RSV could become a preventable problem rather than an annual crisis. A 30% reduction in hospitalizations in seniors and a 72% drop in infant RSV admissions could translate to thousands of saved hospital beds and millions in healthcare savings.

The economic impact is not insignificant. According to the UK’s HSA, infectious diseases now cost the health system £6 billion a year. Widespread RSV vaccination could help reduce this burden.

For most people, <span>RSV symptoms</span> mirror a mild respiratory infection:

<ul><li>Runny nose</li><li>Sneezing</li><li>Cough</li><li>Fatigue</li><li>Mild fever</li></ul>

But signs of severe RSV—especially in babies and older adults—include:

<ul><li>Worsening cough</li><li>Shortness of breath</li><li>Rapid breathing or pauses between breaths</li><li>Feeding difficulties or loss of appetite</li><li>Wheezing</li><li>Confusion (in elderly adults)</li></ul>

Parents should seek medical help immediately if their baby is feeding poorly, breathing quickly, or has noisy or strained breathing.

The UK’s data offers a glimpse into a future where RSV isn’t an annual panic but a preventable illness. It’s a model that can—and likely will—be replicated globally, particularly in countries with well-established maternal care systems.

In the US, the RSV vaccine Abrysvo is already approved for pregnant individuals and adults 60 and older. Pediatricians and public health officials are watching the UK rollout closely, and similar initiatives are being discussed for vulnerable infants in the US and beyond.

As global infectious disease trends evolve, strategies like maternal RSV vaccination could become the new frontline of defense—not only protecting the youngest patients but also relieving overstretched health systems during the winter months.

RSV has long been a silent burden on newborns and hospitals alike but with vaccines for expectant mothers and protective injections for premature babies now in play, we’re finally shifting from reactive care to proactive prevention.

Parents, caregivers, and healthcare providers now have an opportunity to protect infants from RSV before they even take their first breath. The science is solid. The tools are here. Now it’s about getting them into arms.

Health Conditions A-Z

health

rsv vaccine for babies

rsv in infants

rsv symptoms

nirsevimab for preemies

rsv vaccine pregnancy

uk rsv hospitalizations

rsv bronchiolitis prevention

india-digitalizes-health-records-of-100-crore-people-under-ayushman-bharat

India Digitalizes Health Records Of 100 Crore People Under Ayushman Bharat

ebola-outbreak-kerala-to-keep-visitors-from-affected-countries-under-surveillance-for-21-days

Ebola Outbreak: Kerala To Keep Visitors From Affected Countries Under Surveillance For 21 Days

high-bp-1

Post-Pandemic Effect: Why 30-Something Delhi-ites Are Struggling With High BP

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Respiratory syncytial virus, or RSV, is often dismissed as just another cold virus. But in reality, it's the leading cause of hospitalizations for infants under one year of age worldwide. As healthcare systems worldwide wrestle with post-pandemic waves of respiratory illnesses, RSV has emerged as one of the most persistent and potentially dangerous. What’s changing now is how we prevent it—and early data from the United Kingdom shows we might finally be gaining ground.The latest findings, why RSV matters, and how two vaccines—one for pregnant women and one for premature infants—could turn this virus from a winter threat into a manageable infection.RSV typically starts with symptoms that resemble a common cold: runny nose, cough, sneezing, fatigue, and sometimes fever. But in infants, especially those born prematurely or with underlying health conditions, it can progress rapidly into bronchiolitis or pneumonia. These conditions can cause breathing distress, feeding difficulties, and—in the worst cases—require intensive care support.While most full-term babies recover with rest and fluids, around 30,000 children under the age of five are hospitalized every year in the UK due to RSV. Tragically, around 30 of them do not survive. Globally, the burden is even greater, especially in low-resource countries where access to neonatal intensive care is limited.The UK Health Security Agency’s 2023–2025 report revealed that infectious diseases now account for a fifth of all hospital bed usage, at an annual cost of over $7.7 billion. RSV and flu were major drivers of this surge, particularly during winter.But amidst the sobering data was a silver lining: a 30% drop in RSV-related hospitalizations among vaccinated seniors aged 75–79. And even more encouraging—when pregnant women were vaccinated against RSV, the risk of their babies being hospitalized with severe infection dropped by a staggering 72%.This isn’t a small win. It’s a signal that we may finally have tools to lower the burden of RSV across all age groups.How Does the Maternal RSV Vaccine Work?When a pregnant woman receives the RSV vaccine—currently offered in the UK starting at 28 weeks of pregnancy—her body generates antibodies that are passed to the baby in utero. These antibodies offer a protective buffer against RSV during the first six months of life, when infants are most vulnerable.Timing matters. The study led by the University of Edinburgh showed the highest level of protection (72%) was seen when the vaccine was given more than two weeks before delivery. Babies whose mothers were vaccinated at any point before birth still had reduced risk, but the impact dropped to 58%.Despite these results, only about half of pregnant women in England and Scotland are receiving the RSV vaccine. Public health officials are now urging increased uptake to curb RSV admissions this winter.What About Premature Babies Who Miss Maternal Immunity?Babies born before 32 weeks don’t receive as many antibodies from their mothers, making them extremely vulnerable to RSV. Enter nirsevimab—a monoclonal antibody shot that offers immediate and long-lasting protection, not by training the immune system like a vaccine, but by delivering RSV-blocking antibodies directly.Starting in September, the NHS will provide nirsevimab to around 9,000 premature babies across the UK. The single injection provides protection for up to six months—precisely the timeframe these infants are at highest risk.Dr. Claire Fuller, co-national medical director for NHS England, described it as offering “a protective bubble” for at-risk newborns. And early data suggests the drug is more than 80% effective at preventing severe RSV-related illness.Hospitals aren’t just overwhelmed by RSV because of its severity—it’s the sheer volume of cases. Every winter, thousands of RSV cases flood pediatric wards, straining resources, delaying elective procedures, and stressing staff.With effective maternal vaccination and early protection for preemies, RSV could become a preventable problem rather than an annual crisis. A 30% reduction in hospitalizations in seniors and a 72% drop in infant RSV admissions could translate to thousands of saved hospital beds and millions in healthcare savings.The economic impact is not insignificant. According to the UK’s HSA, infectious diseases now cost the health system £6 billion a year. Widespread RSV vaccination could help reduce this burden.What Are the Symptoms of RSV?For most people, RSV symptoms mirror a mild respiratory infection:Runny noseSneezingCoughFatigueMild feverBut signs of severe RSV—especially in babies and older adults—include:Worsening coughShortness of breathRapid breathing or pauses between breathsFeeding difficulties or loss of appetiteWheezingConfusion (in elderly adults)Parents should seek medical help immediately if their baby is feeding poorly, breathing quickly, or has noisy or strained breathing.The UK’s data offers a glimpse into a future where RSV isn’t an annual panic but a preventable illness. It’s a model that can—and likely will—be replicated globally, particularly in countries with well-established maternal care systems.In the US, the RSV vaccine Abrysvo is already approved for pregnant individuals and adults 60 and older. Pediatricians and public health officials are watching the UK rollout closely, and similar initiatives are being discussed for vulnerable infants in the US and beyond.As global infectious disease trends evolve, strategies like maternal RSV vaccination could become the new frontline of defense—not only protecting the youngest patients but also relieving overstretched health systems during the winter months.RSV has long been a silent burden on newborns and hospitals alike but with vaccines for expectant mothers and protective injections for premature babies now in play, we’re finally shifting from reactive care to proactive prevention.Parents, caregivers, and healthcare providers now have an opportunity to protect infants from RSV before they even take their first breath. The science is solid. The tools are here. Now it’s about getting them into arms.

rsv vaccine for expecting moms cuts risk of severe lung infections in infants by 72%; premature babies to be vaccinated before winter

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.